Skip to main content

Cepheid Shares Decline 7.4 Percent on Discounted Share Offering

NEW YORK, March 8 (GenomeWeb News) - Shares of Cepheid were down 7.4 percent, or $.68, at $8.47 in afternoon trading today after the company said it was pricing a secondary stock offering below Wednesday's closing price.

 

As GenomeWeb News reported this morning, Cepheid said it had priced 10 million shares to total $80.5 million, or an individual share price of $8.60, versus Tuesday's closing price of $9.15. This represented an 11.4-percent discount over Tuesday's closing price.

 

The underwriters of the offering have an option to purchase up to an additional 1.5 million shares to cover over-allotments.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.